Rho-Kinase/ROCK as a Potential Drug Target for Vitreoretinal Diseases

Medicine and Dentistry

• Combination Therapy 100%
• Rho Kinase 100%
• Proliferative Vitreoretinopathy 100%
• Diseases 66%
• Attention 66%
• Rho Kinase Inhibitor 66%
• Serositis 33%
• Drug 33%
• Chemotherapeutic Agent 33%
• Pathogenesis 33%
• Malignant Neoplasm 33%
• Amaurosis 33%
• Guanine Nucleotide Binding Protein 33%
• Protein 33%
• Angiogenesis 33%
• Fibrosis 33%
• Pathology 33%
• Cardiovascular Disease 33%
• Vasculotropin 33%
• Mechanism of Action 33%
• Glaucoma 33%
• Diabetic Retinopathy 33%
• Brain Vasospasm 33%
• Age Related Macular Degeneration 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Rho Kinase 100%
• Vitreoretinopathy 100%
• Diseases 66%
• Rho Kinase Inhibitor 66%
• Drug 33%
• Vasculotropin 33%
• Protein 33%
• Malignant Neoplasm 33%
• Blindness 33%
• Pathogenesis 33%
• Guanine Nucleotide Binding Protein 33%
• Cardiovascular Disease 33%
• Diabetic Retinopathy 33%
• Fibrosis 33%
• Molecular Target 33%
• Age Related Macular Degeneration 33%
• Brain Vasospasm 33%
• Glaucoma 33%

Chemistry

• Protein 66%
• Potential 66%
• Inhibitor 66%
• Drug Target 66%
• Application 33%
• Vascular Endothelial Growth Factor 33%
• Disorder 33%
• Proliferative 33%
• Effector 33%
• Cardiovascular 33%